|
|
trastuzumab A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms: | | anti-c-erB-2 Anti-c-erbB2 Monoclonal Antibody Anti-ERB-2 Anti-erbB2 Monoclonal Antibody Anti-HER2/c-erbB2 Monoclonal Antibody Anti-p185-HER2 monoclonal antibody c-erb-2 monoclonal antibody HER2 | | | US brand name: | | Herceptin | | | Abbreviations: | | MOAB HER2 rhuMAb HER2 | | |
|
|